Blueshift Asset Management LLC Buys Shares of 1,260 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Blueshift Asset Management LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,260 shares of the company's stock, valued at approximately $521,000.

Several other hedge funds have also recently bought and sold shares of IDXX. Flossbach Von Storch SE raised its holdings in shares of IDEXX Laboratories by 5,439.3% during the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock valued at $195,696,000 after buying an additional 464,791 shares during the period. William Blair Investment Management LLC grew its position in IDEXX Laboratories by 701.6% in the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock valued at $174,527,000 after acquiring an additional 369,471 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock valued at $179,867,000 after purchasing an additional 316,048 shares during the period. Seilern Investment Management Ltd acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth $113,104,000. Finally, Vontobel Holding Ltd. boosted its stake in shares of IDEXX Laboratories by 90.1% in the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company's stock valued at $173,051,000 after purchasing an additional 198,404 shares during the period. Hedge funds and other institutional investors own 87.84% of the company's stock.

Remove Ads

IDEXX Laboratories Stock Performance

Shares of IDXX traded down $5.94 during mid-day trading on Tuesday, hitting $417.66. The stock had a trading volume of 877,989 shares, compared to its average volume of 552,266. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market cap of $33.85 billion, a PE ratio of 39.14, a PEG ratio of 3.41 and a beta of 1.39. The company's fifty day simple moving average is $437.38 and its two-hundred day simple moving average is $444.44.

Analyst Ratings Changes

IDXX has been the topic of several analyst reports. Leerink Partners began coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Barclays raised their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Bank of America lifted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Finally, Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $533.75.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.